Bank of America Lowers PO on Myriad Genetics Following BRACA Pricing Cut
December 31, 2013 at 13:16 PM EST
In a report published Tuesday, Bank of America analyst Rafael Tejada lowered the price objective on Myriad Genetics, Inc. (NASDAQ: MYGN ) from $31.00 to $25.00, maintaining a Neutral rating, following the Centers for Medicare and Medicaid Services (CMS) confirming BRACA price cuts. According to the report, on Dec.
